3-year dfs results from niche-2 of ipilimumab and nivolumab in dmmr colon cancer
Published 1 month ago • 141 plays • Length 1:30Download video MP4
Download video MP3
Similar videos
-
2:38
niche-3 of nivolumab and relatlimab in dmmr colon cancer compared to niche-2
-
2:46
#esmo22 highlights on neoadjuvant ici in locally advanced dmmr colon cancer: the niche-2 study
-
2:33
updated results for nivolumab in msi-h colorectal cancer
-
2:09
checkmate 032: nivolumab/ipilimumab for urothelial carcinoma
-
1:26
phase i trial of copanlisib nivolumab in patients with richter’s transformation or transformed fl
-
7:29
myriam chalabi, esmo 2022: neoadjuvant immune checkpoint inhibition in mmr-deficient colon cancer
-
5:56
results from checkmate-032, nivolumab and ipilimumab for melanoma
-
4:48
neoadjuvant ipilimumab plus nivolumab in early stage colon cancer
-
2:39
results from the randomized phase iii daunodouble trial
-
4:47
regorafenib nivolumab in mmr proficient advanced crc
-
1:18
the first off-label 3-level cervical adr surgery with the m-6c artificial disc. | dr. todd lanman
-
1:30
immunotherapy options in crc
-
1:40
safety results from phase 3b strong trial of durvalumab in patients with urinary tract carcinoma
-
2:45
dr. wolchok on ipilimumab after complete resection of stage iii melanoma
-
0:33
phase iii volga: durvalumab tremelimumab enfortumab vedotin for neoadjuvant mibc
-
7:02
setting expectations in third-line colorectal cancer
-
1:25
dart vulvar cancer results: dual anti–ctla-4 and anti–pd-1 blockade in rare tumor
-
1:45
the rationale behind the mif-targeting antibody on203 for solid tumors
-
1:45
part 2/6: treatment of birth defects